The Cooper Companies, Inc. (NASDAQ:COO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

The Cooper Companies, Inc. (NASDAQ:COO) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $110.25.

Several equities research analysts have recently issued reports on the stock. Citigroup decreased their price objective on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Robert W. Baird decreased their price objective on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. Piper Sandler reaffirmed an “overweight” rating and set a $115.00 price objective (down from $120.00) on shares of Cooper Companies in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research report on Friday, March 7th. Finally, BNP Paribas raised shares of Cooper Companies to a “hold” rating in a research report on Thursday, March 13th.

Cooper Companies Stock Performance

Shares of COO stock opened at $82.92 on Wednesday. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. Cooper Companies has a 52 week low of $69.81 and a 52 week high of $112.38. The stock has a market capitalization of $16.58 billion, a PE ratio of 42.52, a P/E/G ratio of 2.25 and a beta of 1.08. The firm has a 50 day moving average of $80.19 and a two-hundred day moving average of $90.00.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. On average, research analysts predict that Cooper Companies will post 3.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Cooper Companies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Cooper Companies during the 4th quarter worth $691,000. Highland Capital Management LLC acquired a new stake in Cooper Companies during the 4th quarter worth $4,004,000. Caprock Group LLC acquired a new stake in Cooper Companies during the 4th quarter worth $282,000. Franklin Resources Inc. raised its stake in Cooper Companies by 194.0% during the 3rd quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock worth $5,265,000 after acquiring an additional 32,260 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Cooper Companies by 6.6% in the third quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock valued at $26,295,000 after purchasing an additional 14,687 shares during the period. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.